OFAR 2 - CRC012 Protocol

Participating Sites:

M.D. Anderson Cancer Center Houston, TX	University of California, San Diego (UCSD) Rebecca and John Moores UCSD Cancer Center La Jolla, CA
Dana Farber Cancer Institute Harvard Medical School Boston, MA

Please contact the participating site to setup an appointment or to get more informaiton.

CRC 012: A Phase I-II Study of Rituximab, Oxaliplatin, Fludarabine and Cytarabine in Patients with Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia

Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of oxaliplatin in combination with fludarabine, cytarabine and rituximab in patients with Richter’s transformation, prolymphocytic leukemia (PLL), or refractory/relapsed B-cell chronic lymphocytic leukemia (CLL). Assess the complete response (CR) and partial response (PR) rate to combination therapy of oxaliplatin, fludarabine, cytarabine and rituximab in patients with Richter’s transformation, PLL or refractory/relapsed B-cell CLL. Determine the safety and toxicity profile of combination therapy of oxaliplatin, fludarabine, cytarabine and rituximab in patients with Richter’s transformation, PLL or refractory/relapsed B-cell CLL.